The Expression and Activation of ERK/MAPK Pathway in Human Esophageal Cancer Cell Line EC9706

Overview

Journal Mol Biol Rep

Specialty Molecular Biology

Date 2010 May 14

PMID 20464500

Citations 8

Authors

Shu-Tao Zheng

Qi Huo

Aerziguli Tuerxun

Wen-Jing Ma

Guo-Dong Lv

Cong-Gai Huang

Qing Liu

Xing Wang

Ren-Yong Lin

Ilyar Sheyhidin

Xiao-Mei Lu

Affiliations

Soon will be listed here.

Abstract

While there have been more and more studies concerning mitogen-activated protein kinases (MAPKs) signaling pathways, which control many cellular complex programmes, such as cell proliferation, differentiation, cell death and embryogenesis. However, few studies are carried out about expression and activation of classical MAPKs, extracellular signal-regulated kinase1/2 (ERK1/2) in human esophageal cancer cell line. Therefore, in the present study, we investigated the expression and activation of ERK1/2 in human esophageal cancer cell line EC9706 and human normal esophageal epithelial cell line Heepic, which is as control. This study showed that ERK1/2 was transiently phosphorylated both in EC9706 and Heepic, the kinetics of which were slightly different. To further study the ERK/MAPK signaling pathway in EC9706 and Heepic cell line, U0126 a kind of specific inhibitor of MEK was used. This study showed that U0126 can block the phosphorylation of ERK1/2 in a short time, the complete inhibition concentration for EC9706 and Heepic cell line is 50 and 20 μM, respectively. Incidentally, to further investigate the different roles of ERK1 and ERK2, vector-based short hairpin interference vectors targeted on ERK1/2 was constructed. Moreover, the effective interference target sequence was screened out in a transient transfection manner. MTT experiment showed that ERK2 is more important than ERK1 in the proliferation of EC9706 cells.

Citing Articles

SALL4 in gastrointestinal tract cancers: upstream and downstream regulatory mechanisms.

Wang T, Jin Y, Wang M, Chen B, Sun J, Zhang J Mol Med. 2024; 30(1):46.

PMID: 38584262 PMC: 11000312. DOI: 10.1186/s10020-024-00812-z.

Exploring the Potential of Thymoquinone-Stabilized Selenium Nanoparticles: In HEC1B Endometrial Cancer Cells Revealing Enhanced Anticancer Efficacy.

Gulbay G, Secme M, Ilhan H ACS Omega. 2023; 8(42):39822-39829.

PMID: 37901525 PMC: 10601430. DOI: 10.1021/acsomega.3c06028.

Expression of miR-195 and MEK1 in patients with bladder cancer and their relationship to prognosis.

Yang K, Tang H, Ding M, Guo Y, Kai K, Xiao J Int J Clin Exp Pathol. 2020; 12(3):843-850.

PMID: 31933892 PMC: 6945159.

CXCR7/p-ERK-Signaling Is a Novel Target for Therapeutic Vasculogenesis in Patients with Coronary Artery Disease.

Cao Z, Tong X, Xia W, Chen L, Zhang X, Yu B PLoS One. 2016; 11(9):e0161255.

PMID: 27612090 PMC: 5017667. DOI: 10.1371/journal.pone.0161255.

Gene expression profile of human esophageal squamous carcinoma cell line TE-1.

Cai H, Zhu Z, Sun X, Li Z, Chen Y, Dong G Int J Clin Exp Med. 2015; 8(8):14268-76.

PMID: 26550410 PMC: 4613095.

References

Kamakura S, Moriguchi T, Nishida E . Activation of the protein kinase ERK5/BMK1 by receptor tyrosine kinases. Identification and characterization of a signaling pathway to the nucleus. J Biol Chem. 1999; 274(37):26563-71. DOI: 10.1074/jbc.274.37.26563. View

Lee Jr J, McCubrey J . The Raf/MEK/ERK signal transduction cascade as a target for chemotherapeutic intervention in leukemia. Leukemia. 2002; 16(4):486-507. DOI: 10.1038/sj.leu.2402460. View

Zeng P, Wagoner H, Pescovitz O, Steinmetz R . RNA interference (RNAi) for extracellular signal-regulated kinase 1 (ERK1) alone is sufficient to suppress cell viability in ovarian cancer cells. Cancer Biol Ther. 2005; 4(9):961-7. DOI: 10.4161/cbt.4.9.1912. View

Carthew R . Gene silencing by double-stranded RNA. Curr Opin Cell Biol. 2001; 13(2):244-8. DOI: 10.1016/s0955-0674(00)00204-0. View

Wang N, Dong X, Zhou R, Guo W, Zhang X, Li Y . An investigation on the polymorphisms of two DNA repair genes and susceptibility to ESCC and GCA of high-incidence region in northern China. Mol Biol Rep. 2007; 36(2):357-64. DOI: 10.1007/s11033-007-9187-y. View

LeFloch R, Pouyssegur J, Lenormand P . Single and combined silencing of ERK1 and ERK2 reveals their positive contribution to growth signaling depending on their expression levels. Mol Cell Biol. 2007; 28(1):511-27. PMC: 2223286. DOI: 10.1128/MCB.00800-07. View

Liu X, Yan S, Zhou T, Terada Y, Erikson R . The MAP kinase pathway is required for entry into mitosis and cell survival. Oncogene. 2004; 23(3):763-76. DOI: 10.1038/sj.onc.1207188. View

Wiesenauer C, Yip-Schneider M, Wang Y, Schmidt C . Multiple anticancer effects of blocking MEK-ERK signaling in hepatocellular carcinoma. J Am Coll Surg. 2004; 198(3):410-21. DOI: 10.1016/j.jamcollsurg.2003.10.004. View

Lev D, Kim L, Melnikova V, Ruiz M, Ananthaswamy H, Price J . Dual blockade of EGFR and ERK1/2 phosphorylation potentiates growth inhibition of breast cancer cells. Br J Cancer. 2004; 91(4):795-802. PMC: 2364773. DOI: 10.1038/sj.bjc.6602051. View

10.

Tuschl T . Expanding small RNA interference. Nat Biotechnol. 2002; 20(5):446-8. DOI: 10.1038/nbt0502-446. View

11.

Yeuk-Hon Chan J, Li L, Miao J, Cai D, Lee K, Chui Y . Differential expression of a novel gene BRE (TNFRSF1A modulator/BRCC45) in response to stress and biological signals. Mol Biol Rep. 2009; 37(1):363-8. DOI: 10.1007/s11033-009-9796-8. View

12.

Balmanno K, Cook S . Tumour cell survival signalling by the ERK1/2 pathway. Cell Death Differ. 2008; 16(3):368-77. DOI: 10.1038/cdd.2008.148. View

13.

Lewis T, Shapiro P, Ahn N . Signal transduction through MAP kinase cascades. Adv Cancer Res. 1998; 74:49-139. DOI: 10.1016/s0065-230x(08)60765-4. View

14.

Lambert R, Hainaut P . The multidisciplinary management of gastrointestinal cancer. Epidemiology of oesophagogastric cancer. Best Pract Res Clin Gastroenterol. 2007; 21(6):921-45. DOI: 10.1016/j.bpg.2007.10.001. View

15.

Jemal A, Murray T, Ward E, Samuels A, Tiwari R, Ghafoor A . Cancer statistics, 2005. CA Cancer J Clin. 2005; 55(1):10-30. DOI: 10.3322/canjclin.55.1.10. View

16.

Wang L, Xue L, Yan H, Li J, Lu Y . Effects of ROCK inhibitor, Y-27632, on adhesion and mobility in esophageal squamous cell cancer cells. Mol Biol Rep. 2009; 37(4):1971-7. DOI: 10.1007/s11033-009-9645-9. View

17.

Shama J, Garcia-Medina R, Pouyssegur J, Vial E . Major contribution of MEK1 to the activation of ERK1/ERK2 and to the growth of LS174T colon carcinoma cells. Biochem Biophys Res Commun. 2008; 372(4):845-9. DOI: 10.1016/j.bbrc.2008.05.135. View

18.

Ballif B, Blenis J . Molecular mechanisms mediating mammalian mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK cell survival signals. Cell Growth Differ. 2001; 12(8):397-408. View

19.

Bessard A, Fremin C, Ezan F, Fautrel A, Gailhouste L, Baffet G . RNAi-mediated ERK2 knockdown inhibits growth of tumor cells in vitro and in vivo. Oncogene. 2008; 27(40):5315-25. DOI: 10.1038/onc.2008.163. View

20.

Novarino G, Fabrizi C, Tonini R, Denti M, Malchiodi-Albedi F, Lauro G . Involvement of the intracellular ion channel CLIC1 in microglia-mediated beta-amyloid-induced neurotoxicity. J Neurosci. 2004; 24(23):5322-30. PMC: 6729296. DOI: 10.1523/JNEUROSCI.1170-04.2004. View